Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark F Brady

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Gynecologic Oncology|November 25, 2010
EORTC 55971: does it apply to all patients with advanced state ovarian cancer?Peter G Rose, Mark F Brady
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2016
Reply to F.M. MuggiaMichael A Bookman, Mark F Brady
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2006
Intraperitoneal therapy for ovarian cancer: a treatment ready for prime timeDeborah K Armstrong, Mark F Brady
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2015
Intraperitoneal chemotherapy: long-term outcomes revive a long-running debateMichael A Bookman, Mark F Brady
Rhode Island Medical Journal (2013)|August 29, 2023
A Novel Approach to the Treatment of a Stingray Injury to the AbdomenSamantha Ni, Brian Hawkins, Mark F Brady
Rhode Island Medical Journal (2013)|May 17, 2023
Dermal Toxicity from a Paraquat-Poisoned Patient's UrineAna Castaneda-Guarderas, Mark F Brady, Rebecca Bruccoleri
The New England Journal of Medicine|June 30, 2016
Weekly vs. Every-3-Week Paclitaxel for Ovarian CancerJohn K Chan, Mark F Brady, Bradley J Monk
Wilderness & Environmental Medicine|March 28, 2025
A Historical Review of Military Support for Space Capsule Rescue and Recovery OperationsPrasanna Kumar, Kristin Silvia, Brent Maney, et al.
Gynecologic Oncology|December 31, 2002
Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group studyRussell J Schilder, Mark F Brady, David Spriggs, et al.
Wilderness & Environmental Medicine|March 5, 2023
Treatment of Scorpion Envenomations in the Middle East: Understanding the Stinging ControversyMark F Brady, Prasanna Kumar, Chase Currier, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Gynecologic Oncology|November 25, 2010
EORTC 55971: does it apply to all patients with advanced state ovarian cancer?Peter G Rose, Mark F Brady
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2016
Reply to F.M. MuggiaMichael A Bookman, Mark F Brady
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2006
Intraperitoneal therapy for ovarian cancer: a treatment ready for prime timeDeborah K Armstrong, Mark F Brady
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2015
Intraperitoneal chemotherapy: long-term outcomes revive a long-running debateMichael A Bookman, Mark F Brady
Rhode Island Medical Journal (2013)|August 29, 2023
A Novel Approach to the Treatment of a Stingray Injury to the AbdomenSamantha Ni, Brian Hawkins, Mark F Brady
Rhode Island Medical Journal (2013)|May 17, 2023
Dermal Toxicity from a Paraquat-Poisoned Patient's UrineAna Castaneda-Guarderas, Mark F Brady, Rebecca Bruccoleri
The New England Journal of Medicine|June 30, 2016
Weekly vs. Every-3-Week Paclitaxel for Ovarian CancerJohn K Chan, Mark F Brady, Bradley J Monk
Wilderness & Environmental Medicine|March 28, 2025
A Historical Review of Military Support for Space Capsule Rescue and Recovery OperationsPrasanna Kumar, Kristin Silvia, Brent Maney, et al.
Gynecologic Oncology|December 31, 2002
Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group studyRussell J Schilder, Mark F Brady, David Spriggs, et al.
Wilderness & Environmental Medicine|March 5, 2023
Treatment of Scorpion Envenomations in the Middle East: Understanding the Stinging ControversyMark F Brady, Prasanna Kumar, Chase Currier, et al.
Pageof 7